Afatinib in the treatment of brain metastases of lung cancer with one rare EGFR mutation: a two-case report

Anticancer Drugs. 2022 Jan 1;33(1):112-118. doi: 10.1097/CAD.0000000000001138.


Brain metastasis is one of the common distant metastases of lung cancer. The prognosis of patients with brain metastasis is worse and the survival time is shorter. In this report, we described a rare mutation of EGFR G2607A (rs1050171) in two patients over 50 years of age with brain metastasis of lung cancer. These two patients were both treated with afatinib, followed up for 13 months and 45 months respectively. Both patients showed that the tumor subsided, the curative effect was identified as partial response (PR), no recurrence and progress occurred and still being under follow-up. Our study provides a support that afatinib may be a reasonable therapeutic option for patients with brain metastasis of lung cancer.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / pathology*
  • Afatinib / therapeutic use*
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / genetics
  • Brain Neoplasms / secondary*
  • ErbB Receptors / genetics
  • Female
  • Humans
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology*
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Staging


  • Antineoplastic Agents
  • Afatinib
  • EGFR protein, human
  • ErbB Receptors